Menu Close
Close
Apply Now
Apply Now →

Stem Cell Therapy for Autoimmune Disease

The Role of Regenerative Medicine in Autoimmune Conditions

Regenerative medicine therapies are being studied as a complementary approach for patients managing the chronic inflammatory effects of autoimmune conditions. All protocols are physician-supervised and individualized.
Start your evaluation

Struggling with an Autoimmune Disorder?

When the immune system becomes dysregulated, it can mistakenly attack the body’s own tissues, causing persistent inflammation and pain. Autoimmune disorders are complex, shaped by genetic, environmental, and immunological factors.

UC-MSC treatments are designed to engage the immune system’s regulatory pathways, aiming to support a more balanced immune response. These mechanisms are grounded in peer-reviewed research, though evidence varies by condition and individual clinical profile. For supporting references, visit our Resource Center.

an elderly man s hand is trembling because of park 2024 01 30 21 43 54 utc

Immune Modulation

UC-MSCs secrete anti-inflammatory cytokines, including IL-10 and TGF-β, that may help suppress dysregulated immune signaling. This is the primary reason they’re studied in autoimmune conditions, where an overactive immune response damages the body’s own tissue.

Regulatory T-Cell Support

One studied mechanism is how UC-MSC therapy promotes regulatory T-cell (Treg) activity, which helps maintain immune self-tolerance. Supporting Treg function may help reduce the autoimmune cascade that drives chronic tissue damage.

Tissue and Mucosal Support

UC-MSC-derived exosomes carry growth factors linked to tissue repair. In conditions where chronic inflammation has caused structural damage, joint erosion in RA, or mucosal injury in Crohn’s, this tissue-supportive signaling may factor into overall protocol design.

Autoimmune Conditions Being Studied in UC-MSC Research

UC-MSC and exosome protocols have been explored as a complementary approach in a range of autoimmune conditions, including stem cell therapy for autoimmune disease broadly and condition-specific applications. The following represent areas of current clinical investigation; individual suitability is determined through physician evaluation:

As a stem cell for rheumatoid arthritis and stem cell therapy for rheumatoid arthritis approach, UC-MSCs may help modulate the inflammatory signaling associated with RA. Early-stage research points to a possible link with reduced joint inflammation — but whether it affects joint destruction itself is still under investigation. Patients managing RA symptoms alongside conventional treatment may be evaluated for this as a complementary approach.

As a potential stem cell therapy for lupus approach, UC-MSC protocols are being studied for their ability to modulate the immune dysregulation behind lupus. Every lupus patient presents differently, from mild joint and skin involvement to more systemic organ effects, so clinical evaluation of individual disease activity comes first, before any protocol is considered.

As a stem cell treatment for Crohn's disease approach, UC-MSC and exosome protocols are studied within the broader category of inflammatory bowel diseases. Their immune-modulatory and tissue-repair signaling is relevant to the mucosal injury Crohn's causes. Suitability depends on disease activity, treatment history, and physician evaluation.

UC-MSC applications are being studied as stem cell therapy multiple sclerosis research, particularly for immune modulation relevant to the neuroinflammation seen in multiple sclerosis (MS). This is conceptually different from a stem cell transplant — specifically autologous stem cell transplantation, which uses a patient's own bone marrow-derived cells in certain MS protocols studied elsewhere. UC-MSC therapy at OmniStem is allogeneic: it uses third-party cells, not the patient's own. Exosome signaling relevant to nerve cells and neuroinflammation is an active area of research, particularly for people with MS, including those with progressive MS, where treatment options are more limited.

As a stem cell therapy for psoriasis approach, UC-MSC-derived exosomes are being studied for anti-inflammatory signaling relevant to the immune-driven skin inflammation psoriasis causes.

Beyond these five conditions, UC-MSC and exosome protocols are also studied for Sjögren's syndrome and scleroderma, two more systemic autoimmune conditions involving chronic inflammation, and in scleroderma's case, tissue fibrosis. As with every autoimmune application here, individual clinical evaluation determines suitability.
stem cells for autoimmune conditions

Our Clinical Approach to Autoimmune Disease

OmniStem’s approach to autoimmune conditions is grounded in the current peer-reviewed literature on mesenchymal stromal cell biology and immune regulation. Protocols aim to address the immune mechanisms behind each condition, while supporting tissue health where appropriate.

Outcomes are assessed individually. Autoimmune diseases vary widely in presentation and severity, so no universal outcome can be guaranteed.

UC-MSC

UC-MSCs target immune regulatory mechanisms associated with autoimmune disease. Because they come from Wharton’s Jelly, they have a low immunogenicity profile, which is what makes them suitable for allogeneic (third-party) use under physician-supervised protocols. That’s different from an autologous stem cell transplant, which uses the patient’s own cells. For autoimmune conditions specifically, using a patient’s own immune-dysregulated cells may not offer the same regulatory benefit.

UC-MSC Derived Exosomes

These vesicles carry anti-inflammatory mediators and immunomodulatory signaling molecules that may help support a more balanced immune environment. Because they can cross biological barriers, they’re an active area of research in systemic inflammatory conditions, including exosome therapy for autoimmune disease applications, where whole-cell delivery may not be appropriate or accessible for the affected tissue.

What Patients Have Usually Tried Before Coming to OmniStem

Most patients exploring UC-MSC therapy for autoimmune conditions have already been through a period of conventional management, biologics, immunosuppressants, corticosteroids, or in some MS cases, discussions around autologous stem cell transplantation. For many, that history reflects real, ongoing frustration: conditions that respond only partially, plateau, or come with side effects of their own.

UC-MSC and exosome therapy isn’t positioned as a replacement for necessary conventional care. It’s a complementary approach some patients explore when symptoms persist despite treatment, or when they want an additional avenue to support immune regulation and tissue health. A full clinical evaluation, including current treatment history and disease activity, determines whether someone may be a suitable candidate.

Frequently Asked Questions

Autoimmune disorders occur when the immune system mistakenly attacks the body’s own healthy tissues, leading to chronic inflammation and damage. Umbilical cord–derived mesenchymal stromal cells (U-MSCs) and their exosomes are being studied for their ability to calm this overactive response. They may reduce harmful inflammatory signals, encourage regulatory immune cells that restore balance, and support the repair of tissues already damaged by disease. While results vary, the goal is to address the root cause of autoimmunity rather than only controlling symptoms.

Early studies and clinical experience suggest potential benefits in conditions such as rheumatoid arthritis, lupus (SLE), Crohn’s disease, multiple sclerosis, and psoriasis. Some patients with other chronic inflammatory conditions may also be considered. These applications remain investigational, and not every patient or condition will be appropriate. A detailed medical evaluation is required to determine suitability.

U-MSC and exosome-based therapies have generally shown good safety profiles when produced under strict quality controls. Because they are ethically sourced and carefully processed, the risk of rejection is low. The most common side effects are mild and temporary, such as injection-site soreness, brief fatigue, or inflammation as the body responds. Rare but more serious complications are possible, which is why every patient undergoes thorough screening and monitoring throughout treatment.

No. A stem cell transplant, including autologous stem cell transplantation used in some MS protocols, typically involves harvesting a patient's own bone marrow or blood-derived stem cells, often alongside intensive conditioning treatment, to reset the immune system. UC-MSC therapy at OmniStem is different: it uses allogeneic (third-party) umbilical cord-derived cells administered without the intensive conditioning process associated with a traditional transplant. A physician evaluation can help clarify which category of treatment may be relevant to your specific condition and history.

stem cells for multiple sclerosis

Stem Cell Therapy for Autuimmune Conditions

Inflammation, cellular repair, tissue function. The biology under the surface, reviewed by a physician.

Start Your Evaluation

Your case.

In our hands.

Within 48 hours.

A physician on the OmniStem medical team will review your clinical profile and prepare an initial assessment. What follows is a medical conversation.

Your clinical profile   2 MIN

A brief summary of your health context. The medical team uses this to prepare before your first conversation.

Physician review   48 H

Dr. Montoya or a member of the medical team evaluates your profile individually.

A clinical conversation

Your history, your priorities, and what a protocol designed around your clinical profile might include.

No obligation

The case review is informational. The only timeline that matters is yours.

Step 1

A few questions to begin

These help the medical team understand whether OmniStem’s protocols are appropriate for your situation before we speak.

Check Access 2.0

What is your primary area of health concern?

Select up to three options that best describe your concerns.

Explore Whether a Regenerative Protocol May Be Right for You

A physician on the OmniStem medical team will review your clinical profile and discuss whether UC-MSC-based protocols may be appropriate for your autoimmune condition.
Start your evaluation